NuVasive, Inc. (NASDAQ:NUVA) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Wednesday.

Other equities research analysts have also recently issued reports about the company. TheStreet upgraded NuVasive from a “c+” rating to a “b” rating in a research note on Wednesday, May 3rd. Jefferies Group LLC restated a “buy” rating and set a $84.00 price objective on shares of NuVasive in a research note on Friday, June 30th. Royal Bank Of Canada restated a “buy” rating and set a $76.00 price objective on shares of NuVasive in a research note on Monday, May 15th. BMO Capital Markets restated a “buy” rating and set a $82.00 price objective on shares of NuVasive in a research note on Tuesday, April 11th. Finally, Canaccord Genuity restated a “buy” rating and set a $84.00 price objective (up from $82.00) on shares of NuVasive in a research note on Wednesday, April 26th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $81.00.

NuVasive (NASDAQ NUVA) traded up 2.31% during trading on Wednesday, hitting $80.51. The stock had a trading volume of 663,054 shares. NuVasive has a 52-week low of $56.70 and a 52-week high of $81.06. The stock’s 50-day moving average is $77.38 and its 200-day moving average is $73.93. The stock has a market capitalization of $4.08 billion, a PE ratio of 84.48 and a beta of 1.08.

NuVasive (NASDAQ:NUVA) last issued its quarterly earnings data on Tuesday, April 25th. The medical device company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.01. The firm had revenue of $249.86 million during the quarter, compared to analysts’ expectations of $250.52 million. NuVasive had a return on equity of 12.63% and a net margin of 5.35%. The firm’s quarterly revenue was up 16.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.34 EPS. On average, analysts predict that NuVasive will post $2.01 earnings per share for the current fiscal year.

WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/07/19/nuvasive-inc-nasdaqnuva-stock-rating-upgraded-by-bidaskclub.html.

Large investors have recently added to or reduced their stakes in the stock. Westside Investment Management Inc. acquired a new stake in NuVasive during the first quarter worth approximately $109,000. FNY Partners Fund LP purchased a new position in shares of NuVasive during the first quarter worth $112,000. Neuburgh Advisers LLC raised its position in shares of NuVasive by 18.3% in the first quarter. Neuburgh Advisers LLC now owns 1,552 shares of the medical device company’s stock worth $116,000 after buying an additional 240 shares in the last quarter. SpiderRock Advisors LLC purchased a new position in shares of NuVasive during the first quarter worth $124,000. Finally, Glen Harbor Capital Management LLC raised its position in shares of NuVasive by 18.3% in the first quarter. Glen Harbor Capital Management LLC now owns 2,134 shares of the medical device company’s stock worth $159,000 after buying an additional 330 shares in the last quarter.

About NuVasive

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Analyst Recommendations for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.